Endocrine News

Endocrine News is a monthly publication produced by the Endocrine Society, designed to benefit its members and other interested individuals. This magazine offers a thorough exploration of current trends in endocrinology, along with detailed discussions of newly published studies. The editorial content aims to provide valuable insights, information, and educational resources related to the practice and research of endocrinology. By delivering reliable, timely, and relevant content, Endocrine News keeps the global endocrine community informed and engaged with the latest developments in the field of endocrinology.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Saliva Test One Step Closer to Replacing Blood Work for Adrenal Disorder Diagnosis

3 days ago | endocrinenews.endocrine.org | Derek Bagley

Salivary cortisol and cortisone can be valuable tools in diagnosing adrenal insufficiency (AI), offering non-invasive options for screening and potentially avoiding the need for ACTH stimulation tests in some cases, states a recent study in The Journal of Clinical Endocrinology and Metabolism. Adrenal insufficiency (AI), such as in cases of Addison’s disease and Congenital Adrenal Hyperplasia, is a potentially serious condition characterized by inadequate cortisol production.
Easy Targets: How Endocrine-Disrupting Chemicals Affect Reproductive Endocrinology

4 days ago | endocrinenews.endocrine.org | Derek Bagley

Endocrine-disrupting chemicals are everywhere, and there is seemingly no escape. Polychlorinated biphenyls (PCBs) – previously used in a variety of commercial and industrial applications – have been banned for decades but are still found in soil, sediment, and even certain types of fish, making them “forever chemicals.” Plastic cups had to have stickers on them promising they were bisphenol A (BPA) free.
Hidden Steroids in Arthritis Supplements Raise Serious Adrenal Concerns

1 week ago | endocrinenews.endocrine.org | Derek Bagley

Before you reach for that arthritis supplement, take note: Over-the-counter supplements could contain surreptitious glucocorticoids, notes a new case series study published in The Journal of The Endocrine Society. The study describes 12 patients who developed Cushing syndrome (CS) and/or adrenal insufficiency (AI) after consuming commonly used supplements such as Artri King, Ardosons, and Ajo Rey — none of which disclosed glucocorticoid content on their labeling.
Sriram Gubbi of NIDDK Wins Endocrine Society’s 2025 Endocrine Images Art Competition - Endocrine News

2 weeks ago | endocrinenews.endocrine.org | Derek Bagley

“Cosmic Bubble” image features cells from a thyroid cancer subtype Sriram Gubbi, MD, won the Endocrine Society’s 2025 Endocrine Images Art Competition with his microphotograph of follicular thyroid carcinoma cells titled “The Cosmic Bubble”. The art competition celebrates the beauty of endocrine science as seen through the lens of a microscope.
Boning Up: National Osteoporosis Awareness and Prevention Month

2 weeks ago | endocrinenews.endocrine.org | Derek Bagley

Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis, promote prevention, and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to take a look at some of the recent research focusing on bone health and potential treatment breakthroughs.
Health Challenges in Males with Classic Adrenal Hyperplasia

3 weeks ago | endocrinenews.endocrine.org | Derek Bagley

Males diagnosed with classic congenital hyperplasia (CAH) due to 21-hydroxylase deficiency require lifelong treatment, with adolescence the most challenging treatment period, notes a review article in The Journal of Clinical Endocrinology & Metabolism and a supplement sponsored by Neurocrine Biosciences, Inc., an American biopharmaceutical company that develops for neurological and endocrine-related disorders.
Fracture Liaison Services

1 month ago | endocrinenews.endocrine.org | Mark Newman

Osteoporotic fractures pose a significant threat to the health and independence of older adults worldwide. Despite advances in medical care, only about 20% of individuals who suffer an initial fragility fracture receive appropriate evaluation and treatment aimed at identification and treatment of osteoporosis and therefore remain at high risk for subsequent fractures.
Hoshino Wins Wayne Bardin International Travel Award

1 month ago | endocrinenews.endocrine.org | Mark Newman

The Endocrine Society has selected Yoshitomo Hoshino, MD, PhD, as the recipient of its 2025 C. Wayne Bardin, MD, International Travel Award for his outstanding ENDO abstract and research contributions to the care of patients with bone health disorders. The C. Wayne Bardin, MD, International Travel Award was created in honor of Past President Wayne Bardin, who made remarkable research contributions to both reproductive physiology and contraception throughout his long career.
The Path of Kahn: Q&A with Barbara Kahn, MD, Recipient of the 2025 Roy O. Greep Award for Outstanding Research

1 month ago | endocrinenews.endocrine.org | Glenda Fauntleroy Shaw |Derek Bagley

Barbara Kahn, MD, initially pursued medical school to understand how the human body works and to help patients with chronic illnesses. During her general medicine fellowship, her cross-over study on blood glucose and urine glucose monitoring led to invitations from U.K. researchers to tour their research institutes — a pivotal experience that revealed basic research as an alternate path to her goal of helping people with chronic illnesses live long, gratifying lives.
FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

1 month ago | endocrinenews.endocrine.org | Derek Bagley

Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT trial, long-term extension trial, and a Phase 2 trial in hypercortisolism.